Galapagos wants to find new small molecule species for cancer with BridGene

BridGene Biosciences has arrived on Galapagos island thanks to a $27 million upfront deal to develop new small molecule drugs for cancer.

The biotech will also be up for $700 million in clinical and commercial milestone payments if any of the candidates are successful, plus royalties on resulting sales.